The Efficacy and Safety of Using Intralesional 5-fluorouracil for Basal Cell Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 25, 2023

Primary Completion Date

May 25, 2025

Study Completion Date

May 25, 2025

Conditions
Basal Cell CarcinomaBCC
Interventions
DRUG

5-Fluorouracil

The invistigators want to assess the safety and efficacy of using intralesional 5-FU for the management of different types of BCC (including all the types EXCEPT the infiltrative one), by estimating different outcomes after the intralesional administration of 5-FU to BCC patient. Patients are randomly selected from the outpatient dermatologic clinic in the Aleppo University Hospital (AUH) over a period of 12 months and then these patients are followed up over another 12 months.

OTHER

SURGERY

Total excision of the lesion

Trial Locations (1)

Unknown

RECRUITING

Ibrahim Arnaout, Aleppo

All Listed Sponsors
collaborator

Aleppo University Hospital

UNKNOWN

lead

University of Aleppo

OTHER